Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01418001 · OUTCOME

Pathologic Response

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) · Source last updated 2018-01-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
2 years

What was measured

will be assessed by both MRI and by pathologic review after surgery. An estimate of each response rate and the 95% CI will be provided

Analysis population: No data is available because data was not collected due to lack of accrual.

Groups in this outcome

Pazopanib 400 mg QD

Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination with Pazopanib

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pazopanib 400 mg QD0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
will be assessed by both MRI and by pathologic review after surgery. An estimate of each response rate and the 95% CI will be provided
groups
  1. description
    Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination with Pazopanib
    id
    OG000
    title
    Pazopanib 400 mg QD
population Description
No data is available because data was not collected due to lack of accrual.
reporting Status
POSTED
time Frame
2 years
title
Pathologic Response
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice